EUR 0.07
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.71 Million EUR | 257.94% |
2022 | 479.95 Thousand EUR | -83.49% |
2021 | 2.9 Million EUR | 50.86% |
2020 | 1.92 Million EUR | -82.07% |
2019 | 10.74 Million EUR | -20.85% |
2018 | 13.57 Million EUR | 32.27% |
2017 | 10.26 Million EUR | 338.35% |
2016 | 2.34 Million EUR | 40.81% |
2015 | 1.66 Million EUR | 9.22% |
2014 | 1.52 Million EUR | 82.97% |
2013 | 832.28 Thousand EUR | 567.29% |
2012 | 124.72 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.12 Million EUR | 0.0% |
2023 Q4 | 606.34 Thousand EUR | 0.0% |
2023 FY | 137.19 Thousand EUR | -71.42% |
2023 Q2 | 63.91 Thousand EUR | 0.0% |
2022 Q4 | 1.43 Million EUR | 0.0% |
2022 Q2 | 2.14 Million EUR | 0.0% |
2022 FY | 479.95 Thousand EUR | -83.49% |
2021 FY | 2.9 Million EUR | 50.86% |
2021 Q4 | 3.32 Million EUR | 0.0% |
2021 Q2 | -1.88 Million EUR | 0.0% |
2020 FY | 1.92 Million EUR | -82.07% |
2020 Q2 | 852.56 Thousand EUR | 0.0% |
2020 Q4 | 4.72 Million EUR | 0.0% |
2019 FY | 10.74 Million EUR | -20.85% |
2019 Q2 | 5.31 Million EUR | 0.0% |
2019 Q4 | 5.43 Million EUR | 0.0% |
2018 Q4 | 6.78 Million EUR | 0.0% |
2018 FY | 13.57 Million EUR | 32.27% |
2018 Q2 | 6.79 Million EUR | 0.0% |
2017 Q2 | 4.48 Million EUR | 0.0% |
2017 FY | 10.26 Million EUR | 338.35% |
2017 Q4 | 5.77 Million EUR | 0.0% |
2016 FY | 2.34 Million EUR | 40.81% |
2016 Q4 | 3.12 Million EUR | 0.0% |
2016 Q2 | 3.06 Million EUR | 0.0% |
2015 Q4 | 504.05 Thousand EUR | 0.0% |
2015 FY | 1.66 Million EUR | 9.22% |
2015 Q2 | 1.15 Million EUR | 0.0% |
2014 Q2 | 944.27 Thousand EUR | 0.0% |
2014 Q4 | 578.52 Thousand EUR | 0.0% |
2014 FY | 1.52 Million EUR | 82.97% |
2013 Q3 | 17.58 Thousand EUR | -95.46% |
2013 Q1 | 17.58 Thousand EUR | 0.0% |
2013 Q2 | 387.61 Thousand EUR | 2103.74% |
2013 Q4 | 450.21 Thousand EUR | 2459.66% |
2013 FY | 832.28 Thousand EUR | 567.29% |
2012 Q3 | 8919.00 EUR | 0.0% |
2012 Q1 | 8919.00 EUR | 0.0% |
2012 FY | 124.72 Thousand EUR | 0.0% |
2012 Q4 | 17.58 Thousand EUR | 97.21% |
2012 Q2 | 8919.00 EUR | 0.0% |
2011 Q4 | 8919.00 EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | 58.871% |
ABIVAX Société Anonyme | 127.37 Million EUR | 98.651% |
Adocia SA | 15.62 Million EUR | 89.008% |
Aelis Farma SA | 18.81 Million EUR | 90.871% |
Biophytis S.A. | 14.33 Million EUR | 88.014% |
Advicenne S.A. | 8.21 Million EUR | 79.087% |
genOway Société anonyme | 16.73 Million EUR | 89.736% |
IntegraGen SA | 5.35 Million EUR | 67.904% |
Medesis Pharma S.A. | 1.56 Million EUR | -9.804% |
Neovacs S.A. | 10.34 Million EUR | 83.391% |
NFL Biosciences SA | 4.37 Million EUR | 60.726% |
Plant Advanced Technologies SA | 2.76 Million EUR | 37.864% |
Sensorion SA | 27.05 Million EUR | 93.65% |
Theranexus Société Anonyme | 3 Million EUR | 42.83% |
TME Pharma N.V. | 5.49 Million EUR | 68.747% |
Valbiotis SA | 9.86 Million EUR | 82.592% |
TheraVet SA | 1.64 Million EUR | -4.479% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 91.545% |
DBV Technologies S.A. | 89.4 Million EUR | 98.078% |
Genfit S.A. | 54.8 Million EUR | 96.865% |
GeNeuro SA | 14.35 Million EUR | 88.034% |
Innate Pharma S.A. | 64.57 Million EUR | 97.339% |
Inventiva S.A. | 120.18 Million EUR | 98.571% |
MaaT Pharma SA | 21.59 Million EUR | 92.046% |
MedinCell S.A. | 32.92 Million EUR | 94.782% |
Nanobiotix S.A. | 58.92 Million EUR | 97.085% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 92.717% |
Poxel S.A. | 28.76 Million EUR | 94.028% |
GenSight Biologics S.A. | 32.66 Million EUR | 94.74% |
Transgene SA | 31.23 Million EUR | 94.499% |
Valneva SE | 134.92 Million EUR | 98.727% |